Kisho

Romark Laboratories, L.C. — Rare Disease Pipeline | Kisho

Romark Laboratories, L.C.

Other

Orphan Designations

2 approved, 1 designated

FDA Approvals

Active Trials

Rare Diseases

across 16 areas

News (30d)

Quiet

Romark Laboratories, L.C. is a company with 3 orphan drug designations across 9 rare diseases. 1 active policy bill affects their portfolio.

Competitive Landscape

Diversified Portfolio

Disease-by-disease pipeline progression from orphan designation through clinical trials to FDA approval.

Source: FDA Orphan Drug Designations, ClinicalTrials.gov, Drugs@FDA

Approved: 0

In Trials: 0

Designated Only: 9

9 total diseases

Disease	Drug(s)	Stage
cryptosporidiosis	Alinia	Des.TrialAppr.
diarrheal disease	Alinia	Des.TrialAppr.
intestinal atresia	Alinia	Des.TrialAppr.
intestinal benign neoplasm	Alinia	Des.TrialAppr.
intestinal failure–associated liver disease	Alinia	Des.TrialAppr.
intestinal neoplasm	Alinia	Des.TrialAppr.
malignant carotid body paraganglioma	nitazoxanide	Des.TrialAppr.
post-treatment Lyme disease syndrome	nitazoxanide	Des.TrialAppr.
treatment-refractory schizophrenia	nitazoxanide	Des.TrialAppr.